13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002013341
Total reported value
$642.6M
$642.6M
14 檔
24.0%
The Q4 2024 SEC filing reveals that Foresite Capital Management VI LLC held a total portfolio value of $642.6M, covering 14 public equity positions.
During Q4 2024, Foresite Capital Management VI LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology Inc | Stock-Other | 28.39% | -6.47% | — | |
| 2 | ALMS | Alumis Inc | Stock-Other | 14.72% | -1.73% | — | |
| 3 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 9.35% | -11.77% | EXIT | |
| 4 | ✓ | Rapt Therapeutics Inc | Stock-Other | 8.80% | — | — | |
| 5 | BCAX | Bicara Therapeutics Inc | Stock-Other | 7.37% | — | — | |
| 6 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 6.96% | — | — | |
| 7 | GPCR | Structure Therapeutics Inc | Stock-Other | 5.08% | — | — | |
| 8 | AKRO | Akero Therapeutics Inc | Stock-Other | 4.52% | — | — | |
| 9 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 3.77% | -1.56% | — | |
| 10 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 3.44% | — | — | |
| 11 | ALLO | Allogene Therapeutics Inc | Stock-Other | 3.27% | — | — | |
| 12 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.62% | -0.04% | — | |
| 13 | ✓ | Casi Pharmaceuticals Inc | Stock-Other | 1.68% | — | — | |
| 14 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.02% | — | — |
According to official SEC Form 13F filings, Foresite Capital Management VI LLC reported a total U.S. public equity portfolio value of $642.6M across 14 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CGON, ALMS, 260) accounted for 24.0% of total reported equity market value during Q4 2024.
During Q4 2024, Foresite Capital Management VI LLC's top holdings by market value included CGON (28.4%)、ALMS (14.7%)、260 (9.3%). The largest single position, CGON, represented 28.4% of total portfolio value.
In Q4 2024, Foresite Capital Management VI LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.